Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC)
Int J Radiat Oncol Biol Phys. 2020 Dec 1;108(5):1399-1400.
doi: 10.1016/j.ijrobp.2020.09.022.
Epub 2020 Nov 18.
1 H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL.
2 Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX.
3 Duke University Medical Center, Durham, NC.
4 Duke University Medical Center, Department of Radiation Oncology, Durham, NC.
5 Galera, Malvern, PA.
6 Galera Therapeutics, Malvern, PA.
7 The University of Texas MD Anderson Cancer Center, Houston, TX.
8 Johns Hopkins University School of Medicine, Baltimore, MD.
9 MD Anderson Cancer Center, Houston, TX.
10 (10)University of Oklahoma Health Science Center, Stephenson Cancer Center, Department of Hematology & Oncology, Oklahoma City, OK.
11 (11)The Univ of Texas MD Anderson Cancer Center, Houston, TX.
12 (12)MD Anderson Cancer Center, Department of Biostatistics, Houston, TX.
13 (13)Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
14 (14)Galera Therapeutics Inc., Malvern, PA.
15 (15)Northwell Health Cancer Institute, Lake Success, NY.
16 (16)UT MD Anderson Cancer Center, Houston, TX; (17)Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.